Pharmacokinetics Clinical Trial
Official title:
Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants
NCT number | NCT03161496 |
Other study ID # | 2016[1236] |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 6, 2017 |
Est. completion date | December 2021 |
It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%. Novel oral anticoagulants-NOACs (include rivaroxaban, apixaban, dabigatran and so on) have advantages of convenient use and no need of monitoring, compared with the traditional vitamin K antagonist. With lack of predicted biomarkers, especially the research data of Chinese, it has the important significance in studying individual differences of NOACs in the anticoagulant efficacy and safety, through the pharmacogenomics research. The aim of this study is to determine the polymorphism of drug metabolizing enzymes, drug transporters and drug target genes in Chinese population. By detecting the gene polymorphism, we intend to study the pharmacokinetic/ pharmacodynamics/ pharmacogenomics (PK-PD-PG) correlation of NOACs and provide scientific basis for accurate medication guide for people to use NOACs.
Status | Recruiting |
Enrollment | 1200 |
Est. completion date | December 2021 |
Est. primary completion date | October 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: (I)Chinese Healthy Volunteers - In accordance with the inclusion criteria for each bioequivalence trial of NOACs; - Sign informed consent of the research; - Complete to collect indexes of pharmacodynamics and pharmacogenomics in the cycle with control drug. (II)Chinese Patients - In accordance with anticoagulation indications of NOACs, include prevention of thrombosis in non valvular atrial fibrillation, prevention and treatment of deep vein thrombosis / pulmonary embolism and prevention of thrombosis after knee / hip replacement; - More than 18 years of age, male or female; - Never received NOACs in a month and intend to take NOACs or have received NOACs for more than one week continuously; - sign informed consent. Exclusion Criteria: (I)Chinese Healthy Volunteers - In accordance with the exclusion criteria for each bioequivalence trial of NOACs; (II)Chinese Patients - With history of immunodeficiency disease, including positive HIV index; - Positive Hepatitis B surface antigen (HBsAg) and HCV index; - Combined therapy of CYP3A4 strong inhibitors and P-gp inhibitors (e.g., systemic pyrrole antifungal agents such as ketoconazole, itraconazole, voriconazole and posaconazole; human immunodeficiency virus (HIV) - protease inhibitors such as ritonavir), CYP3A4 strong inducers and P-gp inducers (e.g., rifampicin, phenytoin, phenobarbital, carbamazepine, St. John's Wort, etc.) in 14 days before treatment with NOACs; - Severe liver dysfunction and abnormal renal function; - Include contraindications of NOACs, such as hypersensitivity, active bleeding, moderate or severe liver disease, previous history of intracranial hemorrhage, gastrointestinal hemorrhage in the past 6 months and major operation within 30 days. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Hospital | Beijing | Beijing |
China | Beijing HuiLongGuan Hospital | Beijing | Beijing |
China | Peking University First Hospital | Beijing | Beijing |
China | The Third Hospital of Changsha | Changsha | Hunan |
China | The Second Affiliated Hospital Of Chongqing Medical University | Chongqing | Chongqing |
China | 900 Hospital of the Joint Logistics Team (Original name: Fuzhou General Hospital of Nanjing Militray Command) | Fuzhou | Fujian |
China | Fujian Medical University Union Hospital | Fuzhou | Fujian |
China | Anhui Provincial Hospital(The First Affiliated Hospital Of USTC) | Hefei | Anhui |
China | The affiliated hospital of Inner Mongolia medical university | Hohhot | Neimenggu |
China | The First Affiliated Hospital of Nanchang University | Nanchang | Jiangxi |
China | The Affiliated Hospital of Qingdao University | Qingdao | Shandong |
China | Renji Hospital, School of Medicine, Shanghai Jiao Tong University | Shanghai | Shanghai |
China | Shanghai Public Health Clinical Center | Shanghai | Shanghai |
China | the First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine | Shenyang | Liaoning |
China | The Affiliated Hospital of Jiangnan University, or called Original Wuxi Third Hospital | Wuxi | Jiangsu |
China | Wuxi People's Hospital | Wuxi | Jiangsu |
China | The 7th People's Hospital of Zhengzhou | Zhengzhou | Henan |
Lead Sponsor | Collaborator |
---|---|
Cui Yimin |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of stroke or systemic embolic events (including TIA) | During the observation time, record the incidence of stroke or systemic embolic events (including TIA) after NOACs(rivaroxaban, apixaban, dabigatran) administration by telephone or out-patient clinic. | At 1 year | |
Primary | Incidence of bleeding events | During the observation time, record the incidence of bleeding events after NOACs(rivaroxaban, apixaban, dabigatran) administration by telephone and out-patient clinic, including subcutaneous bleeding, gingival bleeding, gastrointestinal bleeding, intracranial hemorrhage, etc. | At 1 year | |
Secondary | Genotype detected by next generation sequencing | Collect blood specimen before NOACs administration, then detect genotype of NOACs by next generation sequencing. | pre-dose of NOACs (rivaroxaban, apixaban, dabigatran) | |
Secondary | Level of anticoagulant activity assessed by anti-factor Xa activity | Before and after rivaroxaban and apixaban administration, record anti-factor Xa activity detected by blood coagulation tests. | At baseline; at 3 hours, at 8 or 9 hours, at 12 hours for Chinese healthy volunteers, at 48 or 72 hours for Chinese patients | |
Secondary | Level of anticoagulant activity assessed by anti-factor IIa activity | Before and after dabigatran administration, record anti-factor IIa activity detected by blood coagulation tests. | At baseline; at 2 hours, at 4 hours, at 8 hours, at 12 hours for Chinese healthy volunteers, at 72 hours for Chinese patients | |
Secondary | Expression level of miRNA | Before and after NOACs administration, detect the expression level of miRNA about pharmacodynamics. | At baseline; at 2 or 3 hours, at 4 hours (only for dabigatran), at 8 or 9 hours, at 12 hours for Chinese healthy volunteers, at 48 or 72 hours for Chinese patients. | |
Secondary | Expression level of LncRNA | Before and after NOACs administration, detect the expression level of LncRNA about pharmacodynamics. | At baseline; at 2 or 3 hours, at 4 hours (only for dabigatran), at 8 or 9 hours, at 12 hours for Chinese healthy volunteers, at 48 or 72 hours for Chinese patients. | |
Secondary | Incidence of stroke or systemic embolic events in the other observation times | During the other observation time, record the incidence of stroke or systemic embolic events (including TIA) after NOACs(rivaroxaban, apixaban, dabigatran) administration by telephone or out-patient clinic. | At 1 month, 6 months and 2 years (according the actual duration of NOACs taken in patiens) | |
Secondary | Incidence of bleeding events in the other observation times | During the other observation time, record the incidence of bleeding events after NOACs(rivaroxaban, apixaban, dabigatran) administration by telephone and out-patient clinic, including subcutaneous bleeding, gingival bleeding, gastrointestinal bleeding, intracranial hemorrhage, etc. | At 1 month, 6 months and 2 years (according the actual duration of NOACs taken in patiens) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04092725 -
Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04181008 -
Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers
|
Early Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT04406415 -
Oral Nafamostat in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05421312 -
Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip
|
Phase 4 | |
Completed |
NCT02534753 -
A Pharmacokinetics Study of Intravenous Ascorbic Acid
|
Phase 1 | |
Completed |
NCT01636024 -
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594
|
Phase 1 | |
Completed |
NCT01976078 -
Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents
|
N/A | |
Completed |
NCT01682408 -
Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability
|
Phase 1 | |
Completed |
NCT01214941 -
Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol
|
Phase 4 | |
Completed |
NCT01415102 -
A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.
|
Phase 1 | |
Completed |
NCT01208155 -
Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets
|
Phase 1 | |
Completed |
NCT01260025 -
Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor
|
Phase 1 | |
Completed |
NCT00856570 -
A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects
|
Phase 1 | |
Completed |
NCT00746499 -
Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.
|
Phase 1 | |
Completed |
NCT01055964 -
a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients
|
Phase 3 | |
Completed |
NCT00730145 -
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
|
Phase 1 | |
Completed |
NCT01276119 -
The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males
|
Phase 1 | |
Completed |
NCT00983242 -
Drug-Drug Interaction Between Colchicine and Verapamil ER
|
Phase 1 | |
Completed |
NCT00747721 -
Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU
|
Phase 1 |